Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients.

Ascophyllum Nodosum Fucus Vesiculosus chromium glycemic control

Journal

Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585

Informations de publication

Date de publication:
2019
Historique:
received: 16 04 2019
accepted: 25 07 2019
entrez: 2 10 2019
pubmed: 2 10 2019
medline: 2 10 2019
Statut: epublish

Résumé

To evaluate the actions of a combination of polifenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus, InSea2 175 Caucasian patients with type 2 diabetes were randomized to take nutraceutical combination or placebo for 6 months. One hundred and sixty-four cases completed the study. At baseline and after 6 months, glyco-metabolic control and lipid profile were evaluated. Glycated hemoglobin was significantly reduced by the nutraceutical combination, but not by placebo, both compared to baseline ( In conclusion, a nutraceutical combination of polifenolic composition and chromium picolinate in addition to previously taken anti-diabetic therapy can be helpful in reducing glycated hemoglobin in patients with type 2 diabetes mellitus.

Identifiants

pubmed: 31571960
doi: 10.2147/DMSO.S212429
pii: 212429
pmc: PMC6757141
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1861-1865

Informations de copyright

© 2019 Derosa et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Appl Physiol Nutr Metab. 2011 Dec;36(6):913-9
pubmed: 22087795
Microvasc Res. 2010 Mar;79(2):144-9
pubmed: 20079360
Eur Heart J. 2007 Jan;28(1):88-136
pubmed: 17220161
J Intern Med. 2007 Aug;262(2):145-56
pubmed: 17645583
Biofactors. 2016 May;42(3):316-22
pubmed: 27040503
Expert Rev Endocrinol Metab. 2015 May;10(3):297-304
pubmed: 30298772
Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2186-91
pubmed: 16990564
Fundam Clin Pharmacol. 2014 Apr;28(2):221-9
pubmed: 23039403
Mar Drugs. 2017 Nov 15;15(11):null
pubmed: 29140261
Diabetes Technol Ther. 2006 Dec;8(6):677-87
pubmed: 17109600
Horm Metab Res. 2010 Jan;42(1):8-13
pubmed: 19735057
Mar Drugs. 2017 Feb 15;15(2):null
pubmed: 28212301
Phytother Res. 2019 Mar;33(3):791-797
pubmed: 30714233

Auteurs

Giuseppe Derosa (G)

Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy.
Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Maria Divina Pascuzzo (MD)

Ambulatory Center ASL Torino 4 and ASL Città Di Torino, Torino, Italy.

Angela D'Angelo (A)

Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy.

Pamela Maffioli (P)

Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Classifications MeSH